文献速递放疗物理与技术姑息放疗与转移瘤

患者分期与疾病特征对拟议放射肿瘤学替代支付模型(RO-APM)的影响

Impact of Patient Stage and Disease Characteristics on the proposed Radiation Oncology Alternative Payment Model (RO-APM).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-28

该研究比较了Mayo Clinic 2015-2016年按服务付费(FFS)的Medicare放疗报销与2019年拟议的RO-APM报销,纳入2098例患者。结果显示RO-APM在多数瘤种中报销低于历史FFS,且历史报销随分期显著变化,>65岁患者总报销减少9%。

要点

  • RO-APM基础费率报销在膀胱、宫颈、肺、子宫、结直肠、上消化道、头颈、胰腺、前列腺、中枢神经系统和肛管癌中低于历史FFS。
  • RO-APM报销在肝癌和乳腺癌中高于历史FFS。
  • 历史报销随分期(III期 vs I期)显著变化见于乳腺、子宫、肺、头颈和前列腺癌。

核心结论

  • RO-APM将导致该中心报销显著减少,尤其是服务不足人群更常见的癌症。
  • 服务社会经济弱势群体的机构可能面临收入大幅下降,可能进一步减少该弱势人群的可及性。

研究设计与样本

  • 回顾性比较研究,确定2015至2016年在Mayo Clinic接受放疗患者的FFS Medicare报销。
  • 按RO-APM定义疾病分类和支付片段,共识别2098例患者,其中1866例(89%)按RO-APM分类。
  • 1866例中840例(45%)年龄>65岁。

主要发现

  • 乳腺癌(33%)、头颈癌(14%)和前列腺癌(11%)最常见。
  • RO-APM基础费率报销及敏感性分析范围低于历史报销:膀胱(-40%)、宫颈(-34%)、肺(-28%)、子宫(-26%)、结直肠(-24%)、上消化道(-24%)、头颈(-23%)、胰腺(-20%)、前列腺(-16%)、中枢神经系统(-13%)和肛管(-10%)。
  • RO-APM报销高于历史报销:肝癌(+24%)和乳腺癌(+36%)。
  • 历史报销随分期(III期 vs I期)变化:乳腺(+57%,P < .01)、子宫(+53%,P = .01)、肺(+50%,P < .01)、头颈(+24%,P = .01)和前列腺(+13%,P = .01)。
  • >65岁患者RO-APM总放疗报销较历史FFS减少9%(高、中、低调整RO-APM费率分别为-2%、-15%和-27%)。

关键数值与推荐

  • RO-APM基础费率报销及敏感性分析范围与历史FFS报销的比较采用描述性统计。
  • 平均放疗片段报销按疾病部位报告,除淋巴瘤和转移瘤外,并按分期和疾病亚类分层。

临床怎么用

  • 放疗科需关注RO-APM对不同瘤种报销的差异化影响,尤其是膀胱、宫颈、肺等报销降幅较大的瘤种。
  • 服务社会经济弱势群体的机构应评估RO-APM下的收入变化及对患者可及性的潜在影响。

局限性

  • 研究基于单中心(Mayo Clinic)历史数据,结论外推需谨慎。
  • 仅比较了FFS Medicare报销与RO-APM,未涉及其他支付方或临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The proposed Radiation Oncology Alternative Payment Model (RO-APM) released on July 10, 2019, represents a dramatic shift from fee-for-service (FFS) reimbursement in radiation therapy (RT). This study compares historical revenue at Mayo Clinic to the RO-APM and quantifies the effect that disease characteristics may have on reimbursement. METHODS AND MATERIALS: FFS Medicare reimbursements were determined for patients undergoing RT at Mayo Clinic from 2015 to 2016. Disease categories and payment episodes were defined as per the RO-APM. Average RT episode reimbursements were reported for each disease site, except for lymphoma and metastases, and stratified by stage and disease subcategory. Comparisons with RO-APM reimbursements were made via descriptive statistics. RESULTS: A total of 2098 patients were identified, of whom 1866 (89%) were categorized per the RO-APM; 840 (45%) of those were aged >65 years. Breast (33%), head and neck (HN) (14%), and prostate (11%) cancer were most common. RO-APM base rate reimbursements and sensitivity analysis range were lower than historical reimbursement for bladder (-40%), cervical (-34%), lung (-28%), uterine (-26%), colorectal (-24%), upper gastrointestinal (-24%), HN (-23%), pancreatic (-20%), prostate (-16%), central nervous system (-13%), and anal (-10%) and higher for liver (+24%) and breast (+36%). Historical reimbursement varied with stage (stage III vs stage I) for breast (+57%, P < .01), uterine (+53%, P = .01), lung (+50%, P < .01), HN (+24%, P = .01), and prostate (+13%, P = .01). Overall, for patients older than 65 years of age, the RO-APM resulted in a -9% reduction in total RT reimbursement compared with historical FFS (-2%, -15%, and -27% for high, mid, and low adjusted RO-APM rates). CONCLUSIONS: Our findings indicate that the RO-APM will result in significant reductions in reimbursement at our center, particularly for cancers more common in underserved populations. Practices that care for socioeconomically disadvantaged populations may face significant reductions in revenue, which could further reduce access for this vulnerable population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Waddle MR, Stross WC, Vallow LA, et al. Impact of Patient Stage and Disease Characteristics on the proposed Radiation Oncology Alternative Payment Model (RO-APM). Int J Radiat Oncol Biol Phys. 2020. PMID: 32001382. doi:10.1016/j.ijrobp.2019.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。